Perrigo recalling more than 162,500 tubes of acne gel

Perrigo building
Perrigo is recalling 162,534 tubes of an acne gel in the U.S.

Perrigo, already facing pressure from activist investors, is also dealing with another recall, this time for a prescription acne med that has some mold issues.

According to the most recent FDA Enforcement Report, the Dublin-based company several weeks ago began voluntarily recalling 10 lots of clindamycin phosphate and benzoyl peroxide gel. That amounts to 162,534 tubes of the generic version of Duac Gel.

The report says that a small number of tubes of the nonsterile gel may include the presence of mold on the cap. The med is manufactured at a Perrigo plant in Israel.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Perrigo had several significant recalls last year, including 200 million doses of a medication used to fight infections like diaper rash and thrush after a labeling mishap. It also recalled its copy of children's grape-flavored Mucinex after learning that dosing cups may be mismarked, putting children at risk for being overdosed.  

Perrigo has been under pressure from Starboard Value, a hedge fund that owns about 4.6% of the company and which has slammed Perrigo's “woeful” performance. In December, Perrigo said one step it would take to improve its margins was to restructure its Omega Pharma Belgium business. As part of that move, it expects to cut about 80 jobs.

Read more on

Suggested Articles

Baxter Biopharma Services will spend $50 million to expand its facility in Bloomington, Indiana, to include fill-finish technology.

The FDA knocked India's Aurolife for chronic water leaks from its ceiling that may have contaminated multiple generic medicines.

Moderna and the EU have reached a supply deal for 160 million doses of the biotech's mRNA-based COVID-19 vaccine.